alcls 18.51 10 14 2016 20 10 00 cellectis clls 20.11 media library glossary flux rss twitter facebook search form search this site en fr shareholderinvestorscientistjournalistjob opportunities main menucorporatehistorygovernanceexecutive committeeboard of directorsorganization research & innovationimmuno oncologyengineered car t cellschimeric antigen receptorstherapeutic indicationsgene editing productsproduct candidatesucartsmanufacturing news & publicationsthe essentialpress releaseseventsnewsscientific publicationsarchives create innovative medicine through genome engineering and cell therapies news cellectis announces the issuance of u.s. patent 9 458 439 following u.s. patent 8 921 332 issued in december 2014 october 04 2016 read more read the press release cellectis wins 2016 most innovative european biotech sme award for healthcare september 27 2016 read more read the press release focus on immuno oncology cellectis is a biopharmaceutical company with a single goal to develop adoptive immunotherapies for cancer . in order to address unmet medical needs cellectis is developing immunotherapies based on car t cells . the specificity of those allogeneic therapies is that t cells from healthy donors are genetically edited with our proprietary technology talen to seek and destroy cancer cells . this approach could lead to a drug that would be cost effective easily distributed across all geographies and available to patients who don t have enough t cells to undergo an autologous car t therapy based on the patient s own t cells . gene editing t cells which are cells from the immune system can be engineered to express a chimeric antigen receptor or car a molecule that enables them to recognize specific antigens that are present on the surface of cancer cells . by targeting a protein expressed by tumoral cells the car leads the immune system towards cancer which is recognized as harmful . the immune system is then able to attack cancer cells . read more watch the video share price 18.51 10 14 2016 17 59 59 cellectis alcls 20.11 10 14 2016 20 10 00 cellectis clls subsidiary calyxt inc. contact legal notice sitemap